References
- Smith RD, Keogh-Brown MR, Barnett T. Estimating the economic impact of pandemic influenza: an application of the computable general equilibrium model to the UK. Soc. Sci. Med.73(2), 235–244 (2011).
- Hai R, Garcia-Sastre A, Swayne DE, Palese P. A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains. J. Virol.85(14), 6832–6843 (2011).
- Le TV, Mironova E, Garcin D, Compans RW. Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One6(4), e18780 (2011).
- Gorman WL, Gill DS, Scroggs RA, Portner A. The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity. Virology175(1), 211–221 (1990).
- Lyn D, Gill DS, Scroggs RA, Portner A. The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants. J. Gen. Virol.72(Pt 4), 983–987 (1991).
- Kuroya M, Ishida N. Newborn virus pneumonitis (type Sendai). II. The isolation of a new virus possessing hemagglutinin activity. Yokohama Med. Bull.4(4), 217–233 (1953).
- Takimoto T, Hurwitz JL, Coleclough C et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J. Virol.78(11), 6043–6047 (2004).
- Takeda A, Igarashi H, Nakamura H et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J. Virol.77(17), 9710–9715 (2003).
- Slobod KS, Shenep JL, Lujan-Zilbermann J et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine22(23–24), 3182–3186 (2004).
- Villenave R, Touzelet O, Thavagnanam S et al. Cytopathogenesis of Sendai virus in well-differentiated primary pediatric bronchial epithelial cells. J. Virol.84(22), 11718–11728 (2010).
- Ito R, Ozaki YA, Yoshikawa T et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine21(19–20), 2362–2371 (2003).
- Tamura S, Funato H, Hirabayashi Y et al. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine8(5), 479–485 (1990).
- Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J. Infect. Dis.150(6), 851–857 (1984).
Website
- WHO: fact sheet no. 211: Influenza (seasonal) www.who.int/mediacentre/factsheets/fs211/en/index.html